Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)
Whitehawk Therapeutics (WHWK) reported Cost of Revenue of $760000.0 for Q1 2025, up 16.56% year-over-year from $652000.0 in Q1 2024, and down 3.8% quarter-over-quarter from $790000.0 in Q4 2024.
Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 4 years of Cost of Revenue data on file, last reported at $760000.0 in Q1 2025.
- Cost of Revenue for Q1 2025 came in at $760000.0, up 16.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $760000.0 (down 74.87% YoY), and the FY2025 annual result was $760000.0, down 74.87% from the prior year.
- Cost of Revenue slipped to $760000.0 in Q1 2025 per WHWK's latest filing, from $790000.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $927000.0 in Q4 2023 and troughed at $179000.0 in Q1 2022.
- A 4-year average of $609846.2 and a median of $656000.0 in 2023 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 317.57% in 2023, then slipped 14.78% in 2024.
- A 4-year view of Cost of Revenue shows it stood at $222000.0 in 2022, then soared by 317.57% to $927000.0 in 2023, then fell by 14.78% to $790000.0 in 2024, then slipped by 3.8% to $760000.0 in 2025.
- Business Quant data shows WHWK's Cost of Revenue at $760000.0 in Q1 2025, $790000.0 in Q4 2024, and $804000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 760,000.00 |
| Mar 31, 2025 | 760,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Dec 31, 2022 | 222,000.00 |